Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …

At present, six groups of chronic pulmonary hypertension (PH) are described. Among these,
group 1 (and 1′) comprises a group of diverse diseases termed pulmonary arterial …

Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling is implicated in the
pathogenesis of pulmonary arterial hypertension (PAH). We used a transcriptional high …

Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the
pulmonary vasculature, leading to increased pulmonary vascular resistance. The process of …

Chronic hypoxic exposure induces changes in the structure of pulmonary arteries, as well as
in the biochemical and functional phenotypes of each of the vascular cell types, from the …

Recent clinical and experimental studies are redefining the cellular and molecular bases of
pulmonary arterial hypertension (PAH). The genetic abnormalities first identified in …

Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial
obstruction increases pulmonary vascular resistance, which leads to right ventricular (RV) …

Pulmonary arterial hypertension (PAH) is a rare, complex, and progressive disease that is
characterized by the abnormal remodeling of the pulmonary arteries that leads to right …

Transforming growth factor β (TGF-β) superfamily signaling pathways are ubiquitous and
essential regulators of cellular processes including proliferation, differentiation, migration …

The pulmonary vasculature is comprised of three anatomic compartments connected in
series: the arterial tree, an extensive capillary bed, and the venular tree. Although in general …